Braeburn Pharmaceuticals

BRIXADI (MONTHLY DOSING)

Manufacturer:

Braeburn Pharmaceuticals

Brixadi (Monthly Dosing) HCPCS:

J0578

HCPCS Code Descriptor:

Injection, buprenorphine extended-release (brixadi), greater than 7 days and up to 28 days of therapy

Category:

J Code

Brixadi (Monthly Dosing) NDCs:

58284-0264-01, 58284-0296-01, 58284-0228-01

Primary Type:

Anti-Addiction

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Brixadi (Monthly Dosing):

BRIXADI (MONTHLY DOSING) is aligned to the J Code: J0578. BRIXADI (MONTHLY DOSING) is an Anti-Addiction medication produced by Braeburn Pharmaceuticals and administered via the Subcutaneous route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J0578 Added Date:

4/1/24

J0578 Effective Date:

4/1/24

J0578 Deactive Date:

HCPCS Active

Brixadi (Monthly Dosing) billing and coding information can be found through Braeburn Pharmaceuticals at the link below:
Brixadi (Monthly Dosing) patient assistance information can be found through Braeburn Pharmaceuticals at the URL: https://www.brixadi.com/
BRIXADI (MONTHLY DOSING) prescribing information can be found at the link below:
Our team has not yet identified a source of side effect information for BRIXADI (MONTHLY DOSING)

CPT Administration and Place of Service Codes: